Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30076603HIVENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TVIS30026556HIVENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TVIS30026557HIVENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TVIS30026558HIVENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TVIS30026559HIVENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TVIS20039529HPVENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TVIS20017384HPVENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TVIS44037111HTLV-1ENSG00000067704.10protein_codingIARS2NoNo55699Q9NSE4
TCGA Plot Options
Drug Information
GeneIARS2
DrugBank IDDB00167
Drug NameIsoleucine
Target IDBE0002328
UniProt IDQ9NSE4
Regulation Type
PubMed IDs12783542; 14672940; 17095543; 15663927; 16697013
CitationsWang P, Tang Y, Tirrell DA: Incorporation of trifluoroisoleucine into proteins in vivo. J Am Chem Soc. 2003 Jun 11;125(23):6900-6.@@Fukunaga R, Fukai S, Ishitani R, Nureki O, Yokoyama S: Crystal structures of the CP1 domain from Thermus thermophilus isoleucyl-tRNA synthetase and its complex with L-valine. J Biol Chem. 2004 Feb 27;279(9):8396-402. Epub 2003 Dec 12.@@Zhu B, Zhao MW, Eriani G, Wang ED: A present-day aminoacyl-tRNA synthetase with ancestral editing properties. RNA. 2007 Jan;13(1):15-21. Epub 2006 Nov 9.@@Fukunaga R, Yokoyama S: Crystal structure of leucyl-tRNA synthetase from the archaeon Pyrococcus horikoshii reveals a novel editing domain orientation. J Mol Biol. 2005 Feb 11;346(1):57-71. Epub 2004 Dec 19.@@Fukunaga R, Yokoyama S: Structural basis for substrate recognition by the editing domain of isoleucyl-tRNA synthetase. J Mol Biol. 2006 Jun 16;359(4):901-12. Epub 2006 Apr 25.
GroupsInvestigational; Nutraceutical
Direct ClassificationIsoleucine and derivatives
SMILESCC[C@H](C)[C@H](N)C(O)=O
Pathways3-Methylglutaconic Aciduria Type III; 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Demeclocycline Action Pathway; Josamycin Action Pathway; Gentamicin Action Pathway; Lincomycin Action Pathway; Isobutyryl-CoA Dehydrogenase Deficiency; Methacycline Action Pathway; Clarithromycin Action Pathway; Minocycline Action Pathway; Paromomycin Action Pathway; Lymecycline Action Pathway; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency; Troleandomycin Action Pathway; Amikacin Action Pathway; Methylmalonic Aciduria; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Spectinomycin Action Pathway; Doxycycline Action Pathway; 3-Methylglutaconic Aciduria Type IV; Telithromycin Action Pathway; Roxithromycin Action Pathway; Tigecycline Action Pathway; Valine, Leucine, and Isoleucine Degradation; Arbekacin Action Pathway; Isovaleric Acidemia; Chloramphenicol Action Pathway
PharmGKBPA164750430
ChEMBLCHEMBL1233584